Cancer

Dostarlimab Provides Survival Benefits in dMMR Endometrial Cancer and Other Solid Tumors

Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors …

Read more

Show More

Related Articles

Back to top button